TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14646710

Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene (absorbed dose, 95 kGy)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional gamma irradiated polyethylene (absorbed dose, 25-40 kGy)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups (Highly cross-linked and Control)
Number of subjects: 61
Study: 12074203

Group type: EXPERIMENTAL
Intervention: Quinine 400 mg per day
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 10400278

Group type: EXPERIMENTAL
Intervention: Vigorous exercise program
Number of subjects: 86

Group type: COMPARATOR
Intervention: Contact control
Number of subjects: 86
Study: 7488449

Group type: EXPERIMENTAL
Intervention: Vasodilator drug treatment for 12 weeks
Number of subjects: 18
Study: 2035894

Group type: EXPERIMENTAL
Intervention: 2 Hz TENS of the right hand for 45 minutes
Number of subjects: 8

Group type: COMPARATOR
Intervention: Indifferent stimulation of the iliopsoas region (Control)
Number of subjects: 8
Study: 7076372

Group type: EXPERIMENTAL
Intervention: Marathon group counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29774787

Group type: EXPERIMENTAL
Intervention: Attention bias to threat measured using eye gaze tracking
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Clinician rated severity of social anxiety
Number of subjects: 42
Study: 28116649

Group type: EXPERIMENTAL
Intervention: Aflibercept with radiation and concomitant temozolomide
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Aflibercept with adjuvant temozolomide using the 5/28 regimen
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Aflibercept with adjuvant temozolomide using the 21/28 day regimen
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 59
Study: 26730454

Group type: EXPERIMENTAL
Intervention: Lurasidone (20-60 mg/d or 80-120 mg/d)
Number of subjects: 825

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 825
Study: 24956970

Group type: EXPERIMENTAL
Intervention: Aerobic dance training (12 weeks, 3 times per week at 50-70% of heart rate reserve)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no aerobic dance training)
Number of subjects: 120
Study: 21848526

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of glutamate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control condition (isotonic saline injection)
Number of subjects: 9
Study: 19380868

Group type: EXPERIMENTAL
Intervention: rhIL-7 (3 microg/kg and 30 microg/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: rhIL-7
Number of subjects: 11
Study: 17474645

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation in a subtropical climate (Spain)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Pulmonary rehabilitation in a temperate climate (Norway)
Number of subjects: 96
Study: 15710956

Group type: EXPERIMENTAL
Intervention: Special intervention (10-week smoking cessation program with behavior modification and nicotine gum)
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Special intervention
Number of subjects: 5887
Study: 12089836

Group type: EXPERIMENTAL
Intervention: 3D computer animation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Written text (standard flyer)
Number of subjects: 80
Study: 9879698

Group type: EXPERIMENTAL
Intervention: IgM antibodies reacting with the terminal disaccharide of galactose (beta1‐3)N‐acetylgalactosamine
Number of subjects: 0
Study: 8031424

Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg/kg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 14
Study: 2700773

Group type: EXPERIMENTAL
Intervention: 1‐mg dexamethasone suppression test (DST)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1‐mg dexamethasone suppression test (DST) after lorazepam discontinuation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1‐mg dexamethasone suppression test (DST) after theophylline administration
Number of subjects: 10
Study: 166929

Group type: EXPERIMENTAL
Intervention: Influenza A/Hong Kong/68‐ts‐1 [E] (H3N2) virus
Number of subjects: 10

Group type: COMPARATOR
Intervention: Parainfluenza virus only (control)
Number of subjects: 10
Study: 29164609

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral and mindfulness-based group sleep intervention ('Sleep SENSE')
Number of subjects: 123

Group type: COMPARATOR
Intervention: Active control 'study skills' intervention ('Study SENSE')
Number of subjects: 123
Study: 27060930

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily
Number of subjects: 368

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 368
Study: 24720526

Group type: COMPARATOR
Intervention: Zumba
Number of subjects: 118

Group type: COMPARATOR
Intervention: Soccer
Number of subjects: 118

Group type: COMPARATOR
Intervention: Both intervention groups
Number of subjects: 118
Study: 23278906

Group type: COMPARATOR
Intervention: Group C: 1 ml·kg(‐1) of 0.25% ropivacaine injected after needle insertion into the sacral canal
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Group H: 1 ml·kg(‐1) of 0.25% ropivacaine injected after needle pierced the sacrococcygeal ligament under ultrasound guidance
Number of subjects: 140
Study: 19378318

Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 432

Group type: COMPARATOR
Intervention: LNCG
Number of subjects: 432
Study: 18792885

Group type: EXPERIMENTAL
Intervention: High-heat-processed meal (HHPM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-heat-processed meal (LHPM)
Number of subjects: 20
Study: 17323720

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Occlusal splint
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 0
Study: 14638349

Group type: EXPERIMENTAL
Intervention: MTZ trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CIP trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTZ-then-CIP trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CIP-then-MTZ trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pouch endoscopy with biopsy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pouch endoscopy without biopsy
Number of subjects: 0
Study: 11127486

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 9290118

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation at 30 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8365385

Group type: EXPERIMENTAL
Intervention: Linoleic acid diet
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Stearic acid diet
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Trans fatty acid diet
Number of subjects: 55
Study: 3602015

Group type: EXPERIMENTAL
Intervention: Atenolol/diuretic (5 mg amiloride plus 50 mg hydrochlorothiazide once daily)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Atenolol/nifedipine (20 mg nifedipine twice daily)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Atenolol/diuretic
Number of subjects: 98

Group type: COMPARATOR
Intervention: Atenolol/nifedipine
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 98
Study: 2599441

Group type: EXPERIMENTAL
Intervention: Billroth‐II (BII) anastomosis (n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Roux‐en‐Y (RY) anastomosis (n = 8)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Billroth‐II (BII) anastomosis (n = 4, cleared from Campylobacter pylori)
Number of subjects: 17
Study: 31150502

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Antidepressants and Oxytocin
Number of subjects: 23
Study: 26875155

Group type: EXPERIMENTAL
Intervention: Self-management program consisting of six group sessions combined with an eHealth module
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 31
Study: 25462913

Group type: EXPERIMENTAL
Intervention: Exercise on a treadmill at moderate intensity (60‐70% VO2max; AER) for 30 min
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo exercise (PLAC) for 30 min
Number of subjects: 2
Study: 23601522

Group type: EXPERIMENTAL
Intervention: Delimiting preventive medicine treatment (Group 1)
Number of subjects: 12860

Group type: EXPERIMENTAL
Intervention: Routine medicine treatment (Group 2)
Number of subjects: 12860

Group type: COMPARATOR
Intervention: No treatment (Non-intervention group)
Number of subjects: 12860
Study: 21908162

Group type: EXPERIMENTAL
Intervention: Gradual pressure support (PS) reduction without an initial spontaneous breathing trial (SBT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: PS-supported SBT (PS 7cm H(2)O)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Gradual pressure support (PS) reduction without an initial SBT
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 19920273

Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical breast examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast self-examination
Number of subjects: 0
Study: 17120960

Group type: EXPERIMENTAL
Intervention: Ivermectin (12 mg, 200 microg/kg bodyweight)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (40 mg of vitamin B1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12028093

Group type: EXPERIMENTAL
Intervention: Fluoroscopy with laser aiming guide
Number of subjects: 880

Group type: COMPARATOR
Intervention: Fluoroscopy without aiming guide
Number of subjects: 880
Study: 10349922

Group type: EXPERIMENTAL
Intervention: 3 ml lidocaine 1.5% plus 15 microg epinephrine (1:200,000) i.v. at sevoflurane 0.5%
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 3 ml lidocaine 1.5% plus 15 microg epinephrine (1:200,000) i.v. at sevoflurane 1%
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 3 ml lidocaine 1.5% plus 15 microg epinephrine (1:200,000) i.v. at sevoflurane 2%
Number of subjects: 120

Group type: COMPARATOR
Intervention: 3 ml normal saline at sevoflurane 0.5%
Number of subjects: 120

Group type: COMPARATOR
Intervention: 3 ml normal saline at sevoflurane 1%
Number of subjects: 120

Group type: COMPARATOR
Intervention: 3 ml normal saline at sevoflurane 2%
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 3 ml lidocaine 1.5% plus 15 microg epinephrine (1:200,000) i.v. (all concentrations)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 3 ml normal saline (all concentrations)
Number of subjects: 120
Study: 8535466

Group type: EXPERIMENTAL
Intervention: Phonophoresis with .33% dexamethasone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ultrasound with .33% dexamethasone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 28
Study: 1685691

Group type: EXPERIMENTAL
Intervention: Levocabastine (0.5 mg/ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium cromoglycate (20 mg/ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levocabastine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium cromoglycate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levocabastine and Sodium cromoglycate
Number of subjects: 0
Study: 7003383

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 31975537

Group type: EXPERIMENTAL
Intervention: Z-plasty (ZP)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional simple excision (SE)
Number of subjects: 67
Study: 29236527

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 122
Study: 28078825

Group type: EXPERIMENTAL
Intervention: Ethanol 70% + unfractionated heparin 2000 U/mL
Number of subjects: 103

Group type: COMPARATOR
Intervention: Unfractionated heparin 2000 U/mL
Number of subjects: 103
Study: 26603516

Group type: EXPERIMENTAL
Intervention: Good Neighbour Partnership (GNP) in addition to standard care
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 80
Study: 23623156

Group type: EXPERIMENTAL
Intervention: 5-Hz rTMS (500 pulses/session)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 70
Study: 21530557

Group type: EXPERIMENTAL
Intervention: Nicotine (1mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 18382904

Group type: EXPERIMENTAL
Intervention: leuprorelin + hMG
Number of subjects: 0

Group type: COMPARATOR
Intervention: ganirelix + rFSH
Number of subjects: 0
Study: 16972708

Group type: EXPERIMENTAL
Intervention: Adaptive designs in phase III clinical trials
Number of subjects: 0
Study: 12595492

Group type: EXPERIMENTAL
Intervention: AMG 073
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 11042235

Group type: EXPERIMENTAL
Intervention: Transdermal 17‐beta‐estradiol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9038437

Group type: EXPERIMENTAL
Intervention: Mapleson A mode of the Carden system with a mean fresh gas flow of 2.61 min‐1
Number of subjects: 77

Group type: COMPARATOR
Intervention: Circle absorber mode with a mean fresh gas flow of 1.21 min‐1
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Low-flow anaesthesia
Number of subjects: 77
Study: 1732265

Group type: EXPERIMENTAL
Intervention: A-V Impulse System (mechanical prophylaxis for venous thrombo-embolism)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 60
Study: 6542834

Group type: EXPERIMENTAL
Intervention: Glucose (250 ml, 7%)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fructose (250 ml, 7%)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water (250 ml)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glucose (1.3 +/- 0.4 mmol kg d.w.‐1 min‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fructose (2.1 +/- 0.5 mmol kg d.w.‐1 min‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water (2.3 +/- 0.5 mmol kg d.w.‐1 min‐1)
Number of subjects: 8
Study: 30606259

Group type: EXPERIMENTAL
Intervention: Total CTC count cut-off value of 9.5
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Proportion of mesenchymal CTCs cut-off value of 10.7%
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Combined criteria of total CTC count ≥10/5 mL and proportion of mesenchymal CTCs >10.7%
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Nomogram based on combined criteria and clinicopathological characteristics
Number of subjects: 108
Study: 29445928

Group type: EXPERIMENTAL
Intervention: Lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) with prolonged anti-HER2 therapy (18 weeks)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) with standard anti-HER2 therapy (6 weeks)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) with endocrine therapy
Number of subjects: 215

Group type: COMPARATOR
Intervention: Lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) without endocrine therapy
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Prolonged anti-HER2 therapy
Number of subjects: 215
Study: 27567886

Group type: EXPERIMENTAL
Intervention: Rotigotine ≤8 mg/24 h for early PD (HY 1 and 2)
Number of subjects: 2057

Group type: EXPERIMENTAL
Intervention: Rotigotine ≤16 mg/24 h for advanced PD (HY 3 and 4)
Number of subjects: 2057

Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 2057

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2057
Study: 26334249

Group type: EXPERIMENTAL
Intervention: Full-dose TIV (0.5 mL)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Half-dose TIV (0.25 mL)
Number of subjects: 243
Study: 23069270

Group type: EXPERIMENTAL
Intervention: Tomato juice (330 ml/d)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 106
Study: 20497416

Group type: EXPERIMENTAL
Intervention: tolterodine-ER + α-blocker
Number of subjects: 645

Group type: COMPARATOR
Intervention: placebo + α-blocker
Number of subjects: 645
Study: 18718007

Group type: EXPERIMENTAL
Intervention: 600 mcg sublingual misoprostol
Number of subjects: 61

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 61
Study: 16644320

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including provider education, patient education materials, feedback on beta-blocker use, and access to telephone consultation with an HF expert.
Number of subjects: 2631

Group type: COMPARATOR
Intervention: Control practices (no multifaceted intervention).
Number of subjects: 2631
Study: 14668172

Group type: EXPERIMENTAL
Intervention: 300 mg of caffeine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 10824772

Group type: EXPERIMENTAL
Intervention: New Pathway Program (NP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional curriculum
Number of subjects: 100
Study: 9352865

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic stent shunting (TIPS)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy plus propranolol (ES)
Number of subjects: 83
Study: 1490436

Group type: EXPERIMENTAL
Intervention: BPAA gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: diclofenac emulgel
Number of subjects: 0
Study: 3916457

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 22

Group type: COMPARATOR
Intervention: Griseofulvin
Number of subjects: 22
Study: 31053084

Group type: EXPERIMENTAL
Intervention: Simvastatin in ARDS patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vasopressin in sepsis trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone in sepsis trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levosimendan in sepsis trials
Number of subjects: 0
Study: 29105521

Group type: EXPERIMENTAL
Intervention: Standardized parent history-taking training
Number of subjects: 0
Study: 27427502

Group type: EXPERIMENTAL
Intervention: Hilotherapy system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ice bag (cryotherapy)
Number of subjects: 40
Study: 25147328

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 4731

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4731

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d (in subgroup with diabetes mellitus)
Number of subjects: 4731

Group type: COMPARATOR
Intervention: Placebo (in subgroup with diabetes mellitus)
Number of subjects: 4731
Study: 22251025

Group type: EXPERIMENTAL
Intervention: Usual care enhanced by provider education on depression evaluation and management
Number of subjects: 344

Group type: COMPARATOR
Intervention: Quality improvement (QI) intervention designed to improve access to antidepressant medications and/or cognitive behavior therapy
Number of subjects: 344
Study: 19744750

Group type: EXPERIMENTAL
Intervention: Chyme reinfusion (CR)
Number of subjects: 26
Study: 18656720

Group type: EXPERIMENTAL
Intervention: BiClamp forceps tonsillectomy (BT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrocautery tonsillectomy (ET)
Number of subjects: 0
Study: 15812374

Group type: EXPERIMENTAL
Intervention: Attenuation-corrected SPECT
Number of subjects: 116

Group type: COMPARATOR
Intervention: Non-attenuation-corrected SPECT
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Attenuation-corrected SPECT (BMI <30)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Non-attenuation-corrected SPECT (BMI <30)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Attenuation-corrected SPECT (BMI >=30)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Non-attenuation-corrected SPECT (BMI >=30)
Number of subjects: 116
Study: 12587107

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) infusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 10545433

Group type: EXPERIMENTAL
Intervention: Single premature extrastimuli (S(2))
Number of subjects: 30
Study: 7994860

Group type: EXPERIMENTAL
Intervention: Ventricular pacing alone (simulating VT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Atrioventricular sequential pacing (simulating supraventricular tachycardia or VT with intact VA conduction)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Arterial pulse
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Jugular venous pulse (JVP)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: First heart sound
Number of subjects: 21
Study: 2471025

Group type: EXPERIMENTAL
Intervention: Inosine-pranobex (INPX) 1000 mg every 6 hours for 3 months
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Inosine-pranobex (INPX)
Number of subjects: 553

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 553
Study: 169536

Group type: EXPERIMENTAL
Intervention: ACTH 4-10 (30 mg/s.c.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ACTH 4-10
Number of subjects: 18
Study: 31871140

Group type: EXPERIMENTAL
Intervention: IFN-α kinoid (IFN-K)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 185
Study: 31069442

Group type: EXPERIMENTAL
Intervention: Low baseline 25OHD < 25 nmol/L
Number of subjects: 975

Group type: COMPARATOR
Intervention: Baseline 25OHD ≥ 50 nmol/L
Number of subjects: 975
Study: 28325612

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hs‐TnT)
Number of subjects: 1937

Group type: COMPARATOR
Intervention: Conventional troponin T (c‐TnT)
Number of subjects: 1937